Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 6/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | DCK | P27707 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLG | P54098 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993091 | 0.82 | EP300 (0.47) | EP300TLR8 | |
| SCHEMBL19242440 | 0.82 | EP300 (0.44) | EP300ALBP2RX7DCKPOLG | |
| SCHEMBL28189199 | 0.81 | ALB (0.45) | EP300ALBP2RX7DCKPOLG | |
| SCHEMBL12741854 | 0.81 | RPS6KB1 (0.39) | EP300ALBADORA2AALDH1A1 | |
| SCHEMBL12741862 | 0.81 | EP300 (0.41) | EP300ALBP2RX7DCKPOLG | |
| SCHEMBL5201162 | 0.79 | CDK1 (0.35) | EP300CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL11718699 | 0.79 | EP300 (0.43) | EP300CDK1CCNB1CCNE1CDK2 | |
| SCHEMBL12741859 | 0.79 | EP300 (0.45) | EP300ALBADORA2A | |
| SCHEMBL14612879 | 0.79 | EP300 (0.40) | EP300ALBP2RX7TLR8 | |
| SCHEMBL13195153 | 0.79 | ALB (0.37) | EP300ALBDCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20170008855-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2017-01-12 | — | — | US | disclosed |
| US-20170008855-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2017-01-12 | — | — | US | disclosed |
| US-20150111851-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2015-04-23 | — | — | US | disclosed |
| US-20150111851-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2015-04-23 | — | — | US | disclosed |
| US-8916579-B2 | 5-fluoropyrimidinone derivatives | DOW AGROSCIENCES, LLC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916579-B2 | 5-fluoropyrimidinone derivatives | DOW AGROSCIENCES, LLC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2011-04-21 | — | — | US | disclosed |
| US-20110053891-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053891-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | EP300 492/4885ALB 4486/4885CDK1 428/4885 |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | EP300 1865/4885ALB 216/4885CDK1 3192/4885 |
| US-20170008855-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | DDT, CASP5, CYP3A5 | EP300 4722/4885ALB 4756/4885CDK1 2580/4885 |
| US-20150111851-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | DDT, CASP5, CYP3A5 | EP300 4722/4885ALB 4756/4885CDK1 2580/4885 |
| US-20110053891-A1 | 5-FLUOROPYRIMIDINONE DERIVATIVES | DDT, CASP5, CYP3A5 | EP300 4722/4885ALB 4756/4885CDK1 2580/4885 |
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | NUDT1, NT5C3B, NTPCR | EP300 4687/4885ALB 4861/4885CDK1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.